A comparative study of seven and twenty one times levigation of Nishamalaki Churna with Nishamalaki Swarasa in type 2 diabetes

Not Applicable

• Conditions: Health Condition 1: E119- Type 2 diabetes mellitus without complications

• Registration Number: CTRI/2023/04/051694
• Lead Sponsor: ITRA, Jamnagar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Both the sexes having age between 30 to 60 years.

2. Patients having one among chief complaints of Madhumeha (Prabhuta- Avilamutrata, Pipasadhikya, Kshudhadhikya etc.)

3. Known patient of Type 2 diabetes and also the preliminarily diagnosed patients on the basis of signs and symptoms of the disease are confirmed by FBS and PPBS.

4. Patients having Fasting blood sugar level >=126 mg/dl and <=200 mg/dl and or PPBS level >=200 mg/dl and <=350 mg/dl30.

5. Patients on conventional (Allopathic) oral hypoglyemic agents with and without medications for management of diabetes unchanged over period of last 3 months.

Exclusion Criteria

1. Age more than 60 and below 30 years

2. All patients of diabetes mellitus receiving insulin.

3. Patients having Fasting blood sugar level <126 mg/dl and >200 mg/dl and or PPBS level < 200 mg/dl and >350 mg/dl.

4. Malignant and accelerated hypertensive.

5. Patients having chronic complications of Diabetes Mellitus

i. Microvascular: Nephropathy.

ii. Macrovascular: Coronary artery disease (Acute or recent MI), Acute Peripheral vascular disease & Acute Cerebro-vascular episode. And acute complications like Prameha Pidaka (non-healing wound), extensive Localized or systemic virulent infection, Diabetic ketoacidosis.

iii. Other chronic debilitating diseases like STD etc.

6. HIV positive cases.

7. Secondary Diabetes mellitus

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in cardinal signs and symptoms after treatment and at the end of follow upTimepoint: Baseline, 12 weeks and 14 weeks

Secondary Outcome Measures

Name	Time	Method
Improvement in biochemical parameters of bloodTimepoint: 90 days